What is AVXL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.14B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AVXL?

P/E (TTM) is n/a and 52-week range is $1.44 to $9.95 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AVXL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AVXL?

The company profile lists net income (TTM) near $-14M, EPS (TTM) near $-0.15 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Anavex Life Sciences Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 92.7M shares outstanding, ISIN US0327973006 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Anavex Life Sciences Corp

$AVXL

Health Care · Biotechnology

IR Run Scenarios

$1.49

-3.25%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2006-04-13. The firm analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. Its pipeline products include ANAVEX 2-73 (blarcamesine) and ANAVEX 3-7. Its other programs include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037. ANAVEX 2-73 is being developed as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease and Parkinson’s disease, and in an oral liquid once-daily formulation for rare diseases such as Rett syndrome and Fragile X.

Employees

Website

www.anavex.com

IPO

2006-04-13

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)